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Research Article
An aberrant sugar modification of BACE1 blocks its
lysosomal targeting in Alzheimer’s disease
Yasuhiko Kizuka1, Shinobu Kitazume1,*, Reiko Fujinawa1, Takashi Saito2, Nobuhisa Iwata2,3,
Takaomi C Saido2, Miyako Nakano4, Yoshiki Yamaguchi5, Yasuhiro Hashimoto6, Matthias Staufenbiel7,
Hiroyuki Hatsuta8, Shigeo Murayama8, Hiroshi Manya9, Tamao Endo9 & Naoyuki Taniguchi1,**
Abstract
The b-site amyloid precursor protein cleaving enzyme-1 (BACE1),
an essential protease for the generation of amyloid-b (Ab) peptide,
is a major drug target for Alzheimer’s disease (AD). However, there
is a concern that inhibiting BACE1 could also affect several physio-
logical functions. Here, we show that BACE1 is modified with
bisecting N-acetylglucosamine (GlcNAc), a sugar modification
highly expressed in brain, and demonstrate that AD patients have
higher levels of bisecting GlcNAc on BACE1. Analysis of knockout
mice lacking the biosynthetic enzyme for bisecting GlcNAc, GnT-III
(Mgat3), revealed that cleavage of Ab-precursor protein (APP) by
BACE1 is reduced in these mice, resulting in a decrease in Ab
plaques and improved cognitive function. The lack of this modifica-
tion directs BACE1 to late endosomes/lysosomes where it is less
colocalized with APP, leading to accelerated lysosomal degrada-
tion. Notably, other BACE1 substrates, CHL1 and contactin-2, are
normally cleaved in GnT-III-deficient mice, suggesting that the
effect of bisecting GlcNAc on BACE1 is selective to APP. Considering
that GnT-III-deficient mice remain healthy, GnT-III may be a novel
and promising drug target for AD therapeutics.
Keywords Alzheimer’s disease; amyloid-b; BACE1; bisecting GlcNAc; GnT-III
Subject Category Neuroscience
DOI 10.15252/emmm.201404438 | Received 4 August 2014 | Revised 2
December 2014 | Accepted 12 December 2014 | Published online 15 January 2015
EMBO Mol Med (2015) 7: 175–189
Introduction
Alzheimer’s disease (AD) is a devastating dementia, with the
number of patients now estimated to be ~0.5% of the global
population (Abbott, 2011; Selkoe, 2012). Deposition of amyloid-b
(Ab) peptide in the brain is considered to represent the initial event
in disease development (Karran et al, 2011). Ab is generated by the
two-step proteolytic cleavage of amyloid precursor protein (APP),
which is catalyzed by the b-site APP cleaving enzyme-1 (BACE1,
also designated as b-secretase) (Vassar et al, 2014) and c-secretase
(De Strooper & Annaert, 2010). However, when APP is cleaved at
the a-site within the Ab sequence by a-secretase, pathogenic Ab is
not generated. Current trials to develop c-secretase inhibitors have
been unsuccessful due to serious side effects, probably as a result of
disturbing the signaling of Notch (De Strooper et al, 1998), another
substrate for c-secretase. BACE1 protease also has substrates other
than APP (Kuhn et al, 2012; Vassar et al, 2014), including a2,6-
sialyltransferase (Kitazume et al, 2001), P-selectin glycoprotein
ligand-1 (PSGL-1) (Lichtenthaler et al, 2003), APP homolog proteins
(APLP1 and APLP2) (Eggert et al, 2004; Li & Sudhof, 2004; Pastorino
et al, 2004), low-density lipoprotein receptor-related protein (LRP)
(von Arnim et al, 2005), voltage-gated sodium channel (Nav1) b
subunits (Kim et al, 2005; Wong et al, 2005), neuregulins 1 and 3
(NRG1, 3) (Hu et al, 2006; Willem et al, 2006), and neural cell adhe-
sion molecules (L1 and CHL1) (Zhou et al, 2012). Bace1/ mice
display retinal pathology (Cai et al, 2012) and changes in NRG1
signaling, leading to a schizophrenia-like phenotype (Savonenko
et al, 2008) and impaired formation of muscle spindles (Cheret et al,
2013). This indicates that BACE1 also has physiological roles in
addition to its involvement in the pathogenesis of AD.
Increasing evidence shows that aberrant glycosylation is a critical
factor for the development of various diseases (Dennis et al, 2009;
Godfrey et al, 2011; Ohtsubo et al, 2005). Lack of glycosylation
causes dysfunction of target glycoproteins, including impaired
glycoprotein folding (Hebert et al, 2005), poor ligand binding of a
receptor glycoprotein (Wang et al, 2005), or shortened cell surface
retention of a glycoprotein (Dennis et al, 2009; Ohtsubo et al,
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2005). Although the roles of glycans in AD pathology remain
unclear, most AD-related molecules, including APP and its secreta-
ses (a disintegrin and metalloproteinases (ADAMs) and BACE1),
carry glycans, highlighting the possibility that Ab generation could
be regulated by their glycosylation.
Here, we focus on bisecting N-acetylglucosamine (GlcNAc), a
unique N-glycan structure that is highly expressed in the brain
(Fig 1A). Although this sugar modification has been suggested to
suppress cancer metastasis (Taniguchi et al, 2006), its target glyco-
protein and the function of bisecting GlcNAc in the brain have not
been explored. We have previously found that the glycosyltransfer-
ase, GnT-III (encoded by the MGAT3 gene) (Nishikawa et al, 1992),
which is the sole biosynthetic enzyme for bisecting GlcNAc modifi-
cation (Bhattacharyya et al, 2002), is upregulated in the brains of
AD patients (Akasaka-Manya et al, 2010), but how this increase in
bisected glycan contributes to AD pathology remained unclear. In
this study, we have identified BACE1 as a novel in vivo target glyco-
protein for this modification. By analyzing the brains of GnT-III
(Mgat3)-deficient mice, we demonstrate that the sugar modification
promotes AD pathogenesis by delaying BACE1 degradation. Consid-
ering that Mgat3/ mice show almost no phenotypic abnormality in
terms of development, reproduction, hematology, and brain
morphology (Orr et al, 2013; Priatel et al, 1997), our results highlight
the possibility of a novel strategy for developing glycosyltransferase-
targeted AD therapeutics.
Results
AD patients have higher levels of bisecting GlcNAc on BACE1
We have previously found that a GlcNAc-transferase GnT-III
(encoded by MGAT3) that generates bisecting GlcNAc is upregulat-
ed in AD brains (Akasaka-Manya et al, 2010). We also found, using
a lectin E4-phytohemagglutinin (PHA) for detection (Cummings
& Kornfeld, 1982) (Supplementary Fig S1A and B), that
A
D
B C
Figure 1. BACE1 is modified with bisecting GlcNAc in vivo.
A Bisecting GlcNAc modification by GnT-III.
B BACE1 or APP was immunoprecipitated from mouse brains and blotted with E4-PHA lectin (lower) or anti-BACE1 or APP antibodies (upper). hAPP indicates the APP23
transgenic mouse model for AD.
C Proteins from mouse brain membrane fractions were treated with or without PNGase F and then immunoblotted for BACE1 or for syntaxin 6 (loading control).
D LC–MS base peak chromatogram of desialo-alditol N-glycans derived from mouse brain BACE1. To simplify the results, N-glycans were chemically desialylated before
LC–MS analysis. BACE1-specific glycans, judged by comparison with N-glycan structures from anti-BACE1 IgG (shown in Supplementary Fig S2C), are highlighted by
red squares. Asterisks indicate glycans demonstrated by MS/MS analysis to contain a bisecting GlcNAc structure. Numbers in parentheses indicate the charge state.
Source data are available online for this figure.
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bisecting GlcNAc is mainly expressed in neurons (Supplementary
Fig S1C). From these results, we hypothesized that a key molecule
involved in AD pathogenesis is modified with this sugar chain to
modulate disease progression. We first found a clear mobility shift
of BACE1 but not APP in response to GnT-III deficiency (Fig 1B),
even after the enzymatic removal of O-glycans from APP (Supple-
mentary Fig S1D). We also demonstrated that BACE1 but not APP
was recognized by E4-PHA lectin (Fig 1B lower panels and Supple-
mentary Fig S1E). The reactivity of E4-PHA to BACE1 was largely
absent in GnT-III-deficient (Mgat3/) mice. We confirmed that
APP was modified with bisecting GlcNAc in C17 neuroblastoma
cells (Akasaka-Manya et al, 2008), while APP in the brain was not
reactive with E4-PHA (Supplementary Fig S1F), suggesting that
modification of APP with bisecting GlcNAc occurs in a limited
number of cell types (Kitazume et al, 2010) and is non-existent or
negligible in the brain. In addition, we found that nicastrin, the only
glycosylated subunit of c-secretase, was slightly modified with
bisecting GlcNAc (Supplementary Fig S1G) in spite of the presence
of 16 possible N-glycosylation sites. In light of these results, as well
as several previous reports showing that a change in the glycosylation
of nicastrin does not affect c-secretase activity (Herreman et al, 2003;
Schedin-Weiss et al, 2014), we suggest that BACE1 is a likely func-
tional target of bisecting GlcNAc modification in the Ab-generation
pathway.
The mobility difference in BACE1 disappeared after cleavage of
N-glycans by peptide:N-glycanase (PNGase) F (Fig 1C). Further-
more, based on MS/MS analysis of N-glycans released from the
BACE1 immunopurified from mouse brains (Fig 1D; Supplementary
Fig S2A–C), we detected diagnostic ions derived from bisecting
GlcNAc-containing glycans (Supplementary Fig S2D–H), clearly
demonstrating the presence of bisecting GlcNAc on BACE1
N-glycans (Fig 1D, asterisk). These results indicate that BACE1 is
selectively modified with bisecting GlcNAc by GnT-III on its
N-glycan in vivo.
We assumed that the level of bisecting GlcNAc on BACE1
would be increased with disease progression. To test this, BACE1
was immunoprecipitated from the temporal lobe of non-AD, early-
stage AD, and late-stage AD patients and then blotted with E4-PHA
(Fig 2). The lectin reactivity to BACE1 started to increase in early-
stage AD. This indicates that the level of bisecting GlcNAc on
BACE1 is elevated with disease progression in the human brain,
suggesting that this abnormal change in BACE1 glycosylation is
involved in AD pathogenesis by modulating b-site cleavage of
APP.
Loss of bisecting GlcNAc reduces Ab generation and ameliorates
AD pathology in mice
To investigate how bisecting GlcNAc affects the metabolic pathway
of APP in vivo, we analyzed APP metabolites in Mgat3/ mice
crossed with AD model mice expressing human APP (designated
hAPP, the APP23 transgenic mouse model for AD). Western blot of
APP and its cleaved fragments clearly showed that hAPP/Mgat3/
mice had significantly lower levels of the b-C-terminal fragment of
APP (bCTF) and soluble APP cleaved at the b-site (sAPPb) in their
brains than hAPP/Mgat3+/+ mice, whereas the levels of full-length
A
B
Figure 2. BACE1 is abnormally hyper-modified with bisecting GlcNAc in AD patients.
A Summary of clinical and histological data of non-AD control (NC), early-stage AD (eAD) or AD patients.
B BACE1 from temporal lobe membrane fractions of NC, eAD, or AD patients was immunoprecipitated and blotted with E4-PHA (upper) or anti-BACE1 (lower). The
signal intensity of E4-PHA relative to that of BACE1 was calculated (n = 10). The graph shows means  SEM (*P < 0.05; one-way ANOVA with post hoc Tukey–Kramer
test. P = 0.014 for NC versus eAD, P = 0.028 for NC versus AD).
Source data are available online for this figure.
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 2 | 2015
Yasuhiko Kizuka et al Bisecting GlcNAc delays BACE1 degradation EMBO Molecular Medicine
177
APP, aCTF, and sAPPa were comparable (Fig 3), suggesting that
bisecting GlcNAc on BACE1 plays a critical role in the b-cleavage
process.
We next measured the steady-state levels of Ab40 and Ab42 (the
two major isoforms of Ab) in 3- and 12-month-old mouse brains. In
hAPP/Mgat3+/+ mice, both Ab40 and Ab42 levels increased in an
age-dependent manner (Fig. 4A and B), whereas the amounts of
Ab40/42 in both the Tris-buffered saline (TBS)-soluble and guani-
dine (Gu)-HCl-extractable fractions were significantly reduced in the
hAPP/Mgat3/ mouse brains, consistent with the impairment of
b-cleavage by GnT-III deficiency. It should also be noted that a
prominent Ab reduction was observed in 12-month-old mice and
that hAPP/Mgat3+/ mice displayed Ab levels that were intermedi-
ate between those of hAPP/Mgat3+/+ and hAPP/Mgat3/ mice. We
also confirmed a slight but significant reduction in Ab levels in non-
APP-transgenic Mgat3/ mice (Fig 4C), excluding the possibility
that the Ab reduction by GnT-III deficiency is an APP-transgenic
mouse-specific phenomenon. Immunohistochemical analysis
revealed that the number of Ab plaques was markedly decreased in
the hAPP/Mgat3/ mice (Fig 4D), and the synaptic loss and
accumulation of activated astrocytes around Ab plaques (Saito
et al, 2014) observed in hAPP/Mgat3+/+ mouse brains were either
absent or reduced in hAPP/Mgat3/ brains (Supplementary Fig
S3). Moreover, cognitive impairment in hAPP/Mgat3+/+ mice as
measured by the Y-maze test was significantly rescued in hAPP/
Mgat3/ mice (Fig 4E). These results show that deletion of bisect-
ing GlcNAc ameliorates AD-related abnormalities through reduced
Ab deposition caused by impaired b-cleavage.
BACE1 is more localized to late endosomes/lysosomes, leading to
accelerated degradation of BACE1 in Mgat3-deficient mice
One possible explanation for the reduced b-cleavage in hAPP/
Mgat3/ brain is that bisecting GlcNAc on BACE1 affects its cata-
lytic activity. We therefore measured the in vitro enzymatic activity
of BACE1 with or without bisecting GlcNAc using fluorescently
labeled APP-derived peptide. Immunoprecipitated BACE1 from
Mgat3+/+ and Mgat3/ mouse brains showed comparable enzy-
matic activity in vitro (Fig 5A). Likewise, overexpression of either
GnT-III or dominant negative GnT-III had no effect on the enzy-
matic activity of recombinant BACE1-Fc (Supplementary Fig S4A
and B). In addition, a docking model of the tertiary structure of
BACE1 with bisected N-glycans showed that all glycans lie apart
from the catalytic center (Supplementary Fig S4C). Therefore, it is
unlikely that the enzymatic activity of BACE1 is directly modulated
by bisecting GlcNAc, although it is still possible that glycans
exposed at the molecular surface exert an indirect effect due to the
impaired dimerization of BACE1 (Schmechel et al, 2004; Westmeyer
et al, 2004).
We then hypothesized that loss of bisecting GlcNAc results in
abnormal subcellular localization of BACE1, leading to the marked
reduction in Ab generation in cells. To test this, we prepared
mouse embryonic fibroblasts (MEFs) from Mgat3+/+ and Mgat3/
mice and performed subcellular fractionation of BACE1 and APP
by sucrose density gradient centrifugation. We found that BACE1
in Mgat3+/+ MEFs was mainly co-distributed with an early endo-
some marker and APP, whereas in Mgat3/ cells, BACE1 showed
a different distribution from that of APP (Fig 5B). This altered
localization of BACE1 but not of APP was also found in 3-month-
old (Fig 5C) and 12-month-old hAPP/Mgat3/ brains (Supplemen-
tary Fig S4D), although the difference was less than that observed
in Mgat3/MEFs. Immunostaining of mouse brain sections
showed that co-localization of BACE1 and APP was significantly
reduced in the hAPP/Mgat3/ brain (Fig 5D). It was recently
reported that BACE1 is localized in endosomal compartments to
cleave APP (Das et al, 2013), and we confirmed that degradation
of BACE1 protein occurs mainly in lysosomes (Koh et al, 2005) but
not in the proteasome (Fig 5E). We therefore expected that, in the
absence of bisecting GlcNAc, BACE1 would relocate to late endo-
somes/lysosomes. Indeed, we found that BACE1 in the brains of
hAPP/Mgat3/ mice was more co-localized with the late endo-
some/lysosome marker Lamp1 than in hAPP/Mgat3+/+ mice
(Fig 5F). We also stained nicastrin as a control protein and
confirmed that co-localization of nicastrin with Lamp1 was not
altered in hAPP/Mgat3+/+ mice (Fig 5G). Similarly, immunofluores-
cence staining of Mgat3/ primary neurons revealed increased co-
localization of BACE1 but not nicastrin with Lamp1 compared with
the pattern in Mgat3+/+ neurons (Supplementary Fig S4E and F).
A B
Figure 3. Impaired b-site cleavage of APP in Mgat3/ brain.
A, B APP metabolites from 3-month-old mouse brain membrane (A) or soluble (B) fractions were immunoblotted. The signal intensity was quantified (n = 4–5). All
graphs show means  SEM (*P < 0.05; Student’s t-test for (A) bCTF and (B) sAPPa, and Mann–Whitney U-test for the others. P = 0.386 for APP, P = 0.602 for aCTF,
P = 0.045 for bCTF, P = 0.218 for sAPPa, P = 0.022 for sAPPb).
Source data are available online for this figure.
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Taken together, these data suggest that the pathological modifica-
tion of BACE1, bisecting GlcNAc, blocks the lysosomal trafficking
of BACE1 in the brain.
Increased localization of BACE1 to late endosomes/lysosomes
in the absence of GnT-III would enhance its lysosomal degrada-
tion and lead to down-regulation of BACE1 protein. Although we
could not observe a significant reduction in BACE1 protein in
3-month-old hAPP/Mgat3/ mice (Fig 1C), immunohistochemical
(Fig 6A) and Western blot (Fig 6B) analyses demonstrated that
the level of BACE1 was significantly lower in 12-month-old hAPP/
Mgat3/ animals than in age-matched hAPP/Mgat3+/+ mice.
Similar down-regulation of BACE1 was also observed in Mgat3/
MEFs as compared with Mgat3+/+ MEFs (Fig 6C), resulting in a
significant reduction of Ab generation in Mgat3/ MEFs
(Fig 6D).
Golgi-localized gamma adaptin ear-containing ARF-binding 3
(GGA3) has been reported to promote BACE1 degradation by trans-
porting BACE1 from early endosomes to the late endosome/lysosome
pathway (Tesco et al, 2007). Knockdown of GGA3 did not affect
the level of BACE1 mRNA (Supplementary Fig S4G) but partially
rescued the level of BACE1 protein in Mgat3/ MEFs (Fig 6E),
suggesting that BACE1 in these cells is indeed abnormally
targeted to the late endosome/lysosome pathway in a partially GGA3-
dependent manner. These findings indicate that GnT-III deficiency
causes BACE1 protein to be relocated from early endosomes (where
BACE1 is co-localized with APP) to the late endosome/lysosomal
pathway partly via GGA3, eventually leading to increased degradation
in lysosomes.
Impaired BACE1 activity in the absence of GnT-III is somewhat
selective to APP
In addition to APP, BACE1 cleaves several substrate proteins (Hitt
et al, 2012; Kuhn et al, 2012; Vassar et al, 2014; Zhou et al, 2012),
and targeting BACE1 could therefore affect several physiological
phenomena via impaired cleavage of these substrates. Indeed,
A
C D E
B
Figure 4. Reduced Ab load and ameliorated cognitive function in Mgat3/ mouse brain.
A, B Amounts of Ab40 or Ab42 in the TBS-soluble or Gu-HCl-extractable fraction from (A) 3-month-old or (B) 12-month-old hAPP/Mgat3+/+, hAPP/Mgat3+/, or
hAPP/Mgat3/ brains (n = 5). P = 0.015 for TBS Ab40, P = 0.034 for TBS Ab42, P = 0.001 and 0.012 for Gn–HCl Ab40, P = 0.024 for Gn–HCl Ab42 in (A), P = 0.040
for Gn–HCl Ab40, P = 0.047 for Gn–HCl Ab42 in (B).
C Amounts of Ab40 or Ab42 in the TBS-soluble or Gu-HCl-extractable fraction from 3- to 4-month-old Mgat3+/+ or Mgat3/ brains (n = 7–8). An outlier value was
rejected by the Smirnov–Grubbs’ test (P < 0.05). P = 0.045 for Gn–HCl Ab40.
D Immunostaining of Ab plaques in 12-month-old mouse brain (left). Scale bar, 300 lm. The number of FSB-stained Ab plaques in brain sections prepared from
12-month-old male mice was quantified (right) (n = 6). P = 0.004 for hippocampus, P = 0.0003 for cortex.
E The Y-maze test was performed using 12-month-old male Mgat3+/+, Mgat3/, hAPP/Mgat3+/+, or hAPP/Mgat3/ mice (n = 8–10). **P = 0.004 for Mgat3+/+ versus
hAPP/Mgat3+/+, *P = 0.022 for hAPP/Mgat3+/+ versus hAPP/Mgat3/.
Data information: All graphs show means  SEM (*P < 0.05, **P < 0.01. For comparison between two groups, Student’s t-test was used for (C) and (D) cortex, and
Mann–Whitney U-test was performed for (D) hippocampus. In other cases, two-way ANOVA with a post hoc Tukey–Kramer test (A, B) or the Student–Newman–Keuls test
(E) was used.
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recent studies have reported several abnormalities in Bace1/ mice
(Cai et al, 2012; Cheret et al, 2013; Savonenko et al, 2008). Intrigu-
ingly, however, the levels of other BACE1 substrates, full-length
CHL1, and contactin-2, which were significantly increased in
Bace1/ mice due to impaired cleavage, were normal in Mgat3/
mice (Fig 7A). This result indicates that the effect of bisecting
GlcNAc on BACE1 is somewhat selective to APP. In addition,
although a large number of Bace1/ offspring died within 4 weeks
after birth (Fig 7B) (Dominguez et al, 2005), Mgat3+/ intercrosses
produced Mgat3/ mice (23.7%) at normal Mendelian frequency.
Moreover, Mgat3/ mice are generally healthy, fertile, and behav-
iorally normal (Priatel et al, 1997). These findings raise the possibil-
ity that GnT-III-targeted BACE1 inhibition results in fewer side
effects than inhibiting BACE1 itself.
◀ Figure 5. BACE1 is directed to late endosomes/lysosomes in Mgat3/ cells.A BACE1 from 2-week-old mouse brains was immunoprecipitated and immunoblotted (left). Immunoprecipitated BACE1 activity was measured in vitro (right, n = 3).
The values of Bace1/ samples were subtracted as a background. N.S., P = 0.101.
B MEF homogenates were fractionated by sucrose density centrifugation and immunoblotted for BACE1, APP, rab5, or rab7. EE, early endosome; LE, late endosome.
C Brain homogenates were fractionated by sucrose density centrifugation and immunoblotted for BACE1, rab5, or rab9. EE, early endosome; LE, late endosome. Signal
intensities were quantified and are shown in the right graphs.
D Immunostaining of 12-month-old mouse cerebral cortex for BACE1 and APP. A typical image in the vicinity of plaque-forming area is shown for hAPP/Mgat3+/+
brain. The area of co-localization was quantified using random images of cerebral cortex (n = 10). *P = 0.015.
E Immunoblot of BACE1 or GAPDH (loading control) from immortalized MEFs treated with a proteasome inhibitor (MG132) or a lysosome inhibitor (chloroquine; CQ).
F, G Immunostaining of 12-month-old mouse cerebral cortex for BACE1 (F), or nicastrin (G), and Lamp1. LE, late endosome. Scale bar, 10 lm. The area in which
co-localized staining was observed was quantified as a percentage of the total BACE1-positive area (right, n = 10). **P = 0.007.
Data information: All graphs show means  SEM (Student’s t-test).
Source data are available online for this figure.
A C
B E
D
Figure 6. Down-regulation of BACE1 protein in aged Mgat3/ mouse brain.
A Immunostaining of 12-month-old brain sections (cerebral cortex) with anti-BACE1. Scale bar, 100 lm.
B Proteins from the membrane fractions of 12-month-old mouse brains (n = 4–5) were immunoblotted for BACE1, and BACE1 intensity was quantified. *P = 0.044.
C Lysates from MEFs were immunoblotted for APP, BACE1, or GAPDH (loading control), and BACE1 intensity was quantified (n = 4).
D Amount of Ab40 in the culture medium of immortalized MEFs (n = 3). *P = 0.045.
E MEFs were transfected with control siRNA or GGA3-siRNA and then immunoblotted for BACE1, GGA3, or GAPDH (loading control) (n = 6).
Data Information: All graphs show means  SEM (*P < 0.05; Student’s t-test for (B) and the Mann–Whitney U-test for (D)).
Source data are available online for this figure.
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Discussion
In this study, we first show that BACE1 is highly modified with bisect-
ing GlcNAc in the brains of AD patients. Our analyses of GnT-III-
deficient mice show that lack of bisecting GlcNAc causes a shift in the
intracellular localization of BACE1 from early endosomes, where the
substrate APP is mainly localized, to late endosomes/lysosomes,
thereby enhancing its lysosomal degradation. Both events could
contribute to the ameliorated AD-related pathology observed in
GnT-III-deficient mice via a significant reduction in Ab generation
(Fig 8).
The present study revealed that APP is either not modified or
barely modified in the brain (Supplementary Fig S1F), whereas we
previously found that it is modified with bisecting GlcNAc in neuro-
blastoma cells (Akasaka-Manya et al, 2008), indicating that bisect-
ing GlcNAc modification on APP occurs in a limited number of cell
types. How brain glycoproteins undergo specific glycosylation is
another interesting issue.
In addition to Ab generation, the physiological roles of BACE1
should also be highlighted, given that the use of BACE1 inhibitors
as AD therapeutics could disturb these functions. Abnormal pheno-
types have been reported in BACE1-deficient mice, including a
schizophrenia-like phenotype (Savonenko et al, 2008), abnormal
muscle spindle formation (Cheret et al, 2013), and retinal pathology
(Cai et al, 2012). Moreover, recent proteomic studies have identified
an increased number of novel BACE1 substrates (Kuhn et al, 2012;
Zhou et al, 2012), the biological consequences of whose proteolytic
cleavage by BACE1 have not yet been clarified. Unlike BACE1-
deficient mice, GnT-III-deficient mice do not display significant
abnormalities (Orr et al, 2013; Priatel et al, 1997), exhibiting only a
slight increase in B-220-positive cells and lower vertical activity (Orr
et al, 2013). Although mutant mice expressing truncated GnT-III
have been reported to exhibit several neurological defects such as
impaired leg clasp reflex, these abnormalities are considerably
milder than those observed in Bace1/ mice and are not seen in
GnT-III-deficient mice (Bhattacharyya et al, 2002), suggesting that
they derive from the presence of truncated GnT-III and not from the
loss of full-length GnT-III. These results suggest that inhibiting
GnT-III activity would have fewer side effects than the administra-
tion of BACE1 inhibitors. Taken together, our findings shed light on
the advantages of considering the development of glycan-targeted
drugs for AD treatment.
Recent reports have shown that BACE1 is recycled between
the Golgi network, the plasma membrane, and endosomes (Tan &
Evin, 2012) and that endosomal localization of BACE1 is regu-
lated by GGAs and the retromer, a multiprotein complex required
for the recycling of transmembrane proteins from endosomes to
the trans-Golgi network. Knockdown of vacuolar protein sorting
(Vps) 35, a retromer complex component, results in increased
BACE1 localization in endosomes, and Vps35+/ mice display
increased Ab generation and deposition (Wen et al, 2011). In
contrast, the exit of BACE1 from endosomes toward lysosomes is
mediated by GGAs, particularly GGA3, which is supported by the
finding that Gga3/ brains show increased levels of BACE1
protein (Walker et al, 2012). Knockdown of GGA3 partially
rescued the instability of BACE1 in Mgat3/ cells, indicating that
the absence of bisecting GlcNAc directs BACE1 to the GGA3-
mediated lysosomal pathway. It seems that the physical interaction
of BACE1 with GGA3 involves the cytoplasmic region of BACE1
and is regulated by BACE1 ubiquitination at the C-terminus
(Kang et al, 2010), whereas bisected glycans on BACE1 are
located in its luminal region, suggesting that an unidentified
molecule recognizes bisecting GlcNAc on BACE1 and mediates the
interaction between BACE1 and GGA3. We are currently attempting
to identify an endogenous lectin-like molecule that displays
these properties.
It has been shown that BACE1 is a stress-responsive protease
(Kao et al, 2004; Vassar et al, 2014), and increased BACE1 activity
A B
Figure 7. Limited impairment of BACE1 activity in Mgat3/ brain.
A Membrane fractions from 3-week-old Mgat3+/+, Mgat3/, and Bace1/ mice were immunoblotted for CHL1 (upper), contactin-2 (middle), or syntaxin 6 (lower)
(n = 4–5). The graphs show means  SEM (**P < 0.01; two-way ANOVA with post hoc Tukey–Kramer test, P = 0.006 for Mgat3+/+ versus Bace1/, P = 0.008 for
Mgat3/ versus Bace1/ in CHL1/syn6, P = 0.001 for Mgat3+/+ versus Bace1/, P = 0.002 for Mgat3/ versus Bace1/ in Contactin-2/syn6).
B Number of pups surviving at 4 weeks following a cross between heterozygous male and female mice.
Source data are available online for this figure.
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has been observed in AD patients (Yang et al, 2003). Our findings
demonstrate that BACE1 is highly modified with bisecting GlcNAc
in AD patients. Given that bisecting GlcNAc modification is protec-
tive for lysosomal degradation of BACE1, we believe that stabiliza-
tion of BACE1 by this glycan modification also results in enhanced
Ab production in AD patients. Moreover, our finding that BACE1
protein is down-regulated in aged Mgat3/ mice suggests that the
regulation of BACE1 by bisecting GlcNAc modification is enhanced
with age. Although several studies have previously reported that
Ab-induced stress enhances GnT-III expression in immune cells
from AD patients (Fiala et al, 2007, 2011), understanding how
neuronal GnT-III expression is regulated by oxidative damage or
other forms of stress during AD progression remains a topic for
future investigation.
Materials and Methods
Antibodies and lectin
The commercially available antibodies used were as follows: rabbit
anti-BACE1 (5606), anti-nicastrin (9447S), anti-GGA3 (8027), anti-
rab5 (3547), anti-rab7 (9367), and anti-rab9 (5118) from Cell Signal-
ing Technology; anti-APP C-term (recognizes C-terminal part of
APP, 18961), anti-APP N-term (10D1), and anti-sAPPb-sw (10321,
clone 6A1) from Immuno-Biological Laboratories; anti-Ab (SIG-
39220, clone 4G8) and anti-sAPPa (SIG-39320, clone 6E10) from
SIGNET; anti-Lamp1 (ab25630) and anti-PSD95 (ab2723) from
Abcam; anti-actin (A4700) from Sigma; anti-syntaxin 6 (610635)
from BD Biosciences; anti-GAPDH (MAB374), anti-APP (22C11),
and anti-MBP (MAB386) from Millipore; anti-MAP2 (sc-20172) from
Santa Cruz Biotechnology; anti-GFAP (13-0300) from Life Technolo-
gies; anti-CHL1 (AF2147) and anti-contactin-2 (AF4439) from R&D
systems; and anti-Iba1 (019-197419) from Wako. Biotinylated eryth-
roagglutinating phytohemagglutinin (E4-PHA) lectin was from
Seikagaku Corporation.
Mutant mice
The generation of the Mgat3-deficient mice, Bace1-deficient mice,
and transgenic mice expressing human APP with the Swedish muta-
tion (APP23) has been described previously (Luo et al, 2001; Priatel
et al, 1997; Sturchler-Pierrat et al, 1997). All mice were from a
C57BL/6 genetic background. Mgat3-deficient mice were generously
provided by Dr. Jamey D. Marth (University of California-Santa
Barbara). Mice were housed (3 or fewer mice per cage) at 23  3°C
and 55  10% humidity. The light conditions were 14 h : 10 h
(lights on at 7:00). All animal experiments were approved by the
Animal Experiment Committee of RIKEN.
Staining of Ab plaques
For immunostaining, 12-month-old mouse brains (three mice per
genotype) were fixed with 4% paraformaldehyde in PBS and
embedded in paraffin. Paraffin-embedded coronal sections (5 lm
thick) were de-paraffinized according to a standard method and
then dipped in 90% formic acid for 5 min. After washing with
water (5 min), 0.3% H2O2 in methanol (30 min), water (10 min),
and PBS (3 min), the sections were blocked with 3% BSA in PBS
for 30 min, followed by overnight incubation with the primary
antibody (1:200 dilution; 4G8). The sections were then incubated
with biotinylated anti-mouse IgG, followed by HRP-avidin using
the VECTASTAIN ABC standard kit (Vector Laboratories). Signals
were visualized by DAB staining. For quantification of the number
of Ab plaques, frozen sections (30 lm thick) from 12-month-old
male mice (six mice per genotype) were incubated with 0.05%
Figure 8. Schematic model of results.
Lack of bisecting GlcNAc relocates BACE1 from early endosomes (Ab generation site) to lysosomes, leading to a reduction in both Ab generation and the level of BACE1 protein.
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(w/v) FSB (Dojindo) in EtOH/PBS (1/1, v/v) for 30 min at room
temperature and then washed three times with EtOH/PBS (1/1).
Fluorescence was visualized using an Olympus FV-1000 confocal
microscope.
Preparation of membrane and soluble fractions from
mouse brain
Brains were homogenized with seven volumes of TBS containing a
protease inhibitor cocktail (Roche) using a Potter-style tissue
grinder. Homogenates were ultracentrifuged at 100,000 × g for
30 min at 4°C, and the resultant pellet and supernatant were used
as the membrane and soluble fractions, respectively.
Glycosidase treatment
For PNGase F treatment, proteins (50 lg) were denatured by boiling
in 20 ll of PBS containing 0.5% SDS, 1% 2-mercaptoethanol, and
4 mM EDTA. After the solution had been diluted with four volumes
of PBS containing Nonidet P-40 (NP-40, final concentration 0.5%),
PNGase F (1,000 units, New England Biolabs) was added, and the
solution was incubated for 3 h at 37°C. For sialidase and O-glycosi-
dase treatment, APP was first immunoprecipitated from mouse
brain membrane fraction. After washing the beads with TBS/0.1%
NP-40, immobilized APP was incubated with 10 mU sialidase
(Arthrobacter ureafaciens, Nacalai tesque) with or without 1.5 mU
O-glycosidase (Roche) in acetate buffer (100 mM sodium acetate pH
4.5, 50 mM NaCl, 0.1% NP-40, 1 mM EDTA, protease inhibitor
cocktail) for 12 h at 37°C.
Lectin pulldown and immunoprecipitation
For lectin pulldown, the membrane fraction (obtained from 250 ll
of homogenate) was solubilized with 750 ll of TBS containing
1% Triton X-100 and a protease inhibitor cocktail (Roche) and
then ultracentrifuged at 100,000 × g for 15 min. The supernatant
was incubated with 100 ll of E4-PHA-agarose (Seikagaku Corpora-
tion) for 2 h at 4°C. The beads were washed twice with an excess
volume of TBS containing 0.1% Triton X-100, and the bound
proteins were eluted with SDS sample buffer. For immunoprecipi-
tation, the membrane fraction (obtained from 250 ll of homoge-
nate) or cell pellet (obtained from a 10-cm dish) was lysed with
TBS (750 ll for the brain membrane fraction and 500 ll for the
cell pellet) containing 0.5% NP-40 and protease inhibitor cocktails
and then ultracentrifuged at 100,000 × g for 15 min. The superna-
tant was incubated with antibody (3–5 lg) for 10 min at 4°C,
after which protein G-Sepharose 4 Fast Flow (20 ll, GE Health-
care) was added to the mixture, followed by rotation for 2 h at
4°C. The beads were washed three times with TBS containing
0.1% NP-40, and bound proteins were eluted with SDS sample
buffer.
Y-maze test
The Y-maze test was performed using 12-month-old male mice as
described previously with minor modifications (Saito et al, 2011).
Tests were performed at a light intensity of 90 lx at the level of the
platform.
Western and lectin blotting
Proteins were separated by 4–20% gradient SDS–PAGE and then
transferred to PVDF or nitrocellulose membranes. After incubation
with 5% non-fat dried milk in TBS containing 0.1% Tween-20, the
membranes were incubated with primary antibody, followed by
HRP-conjugated secondary antibody. Signals were detected with
SuperSignal West Dura Extended Duration Substrate (Thermo
Scientific) using ImageQuant LAS-4000mini (GE Healthcare). For
lectin blotting, nitrocellulose membranes were blocked with TBS
containing 0.1% Tween-20 for 30 min at room temperature. The
membranes were then incubated with biotinylated E4-PHA lectin
(1:500) that had been diluted with TBS containing 0.1% Tween-20,
followed by incubation with HRP-avidin (VECTASTAIN ABC
Standard Kit). The intensity of the resultant protein bands was
quantified using ImageQuant TL software (GE Healthcare). For
quantification of the levels of APP metabolites and BACE1, proteins
from the brains of 3-month-old (three male and two female) and
12-month-old (two male and three female) mice were analyzed.
Each set of experiments was repeated at least three times to confirm
the results.
Ab ELISA
Ab ELISA was performed as described previously (Iwata et al,
2004; Saito et al, 2011) with slight modifications. Brains from
3-month-old (three male and two female) and 12-month-old (two
male and three female) hAPP mice or from 3- to 4-month-old (six
male and two female) non-hAPP mice were homogenized with
seven volumes of TBS containing a protease inhibitor cocktail
(Roche) using a Potter-style tissue grinder. Homogenates were ultra-
centrifuged at 100,000 × g for 30 min at 4°C, and the resultant
supernatant was used as a TBS-soluble fractions. The pellet was
then homogenized again in TBS and ultracentrifuged at 100,000 × g
for 10 min at 4°C. The resultant pellet containing insoluble and
membrane-associated Ab was suspended in 10 volumes of buffer
(50 mM Tris–HCl, 6 M guanidine, protease inhibitor cocktail, pH
7.6) and sonicated. After incubation for 1 h at room temperature, a
Gu-HCl-extracted fraction was obtained by ultracentrifugation at
100,000 × g for 20 min at 25°C. For ELISA, the Gu-HCl fraction was
diluted 12-fold with phosphate buffer, and a 1/11 volume of 6M
Gu-HCl was added to the soluble fraction to normalize the effect of
Gu-HCl. ELISA was carried out using the Human/Rat bamyloid (40)
ELISA kit and Human/Rat bamyloid (42) ELISA kit High-Sensitive
(Wako). The values in Bace1/ mice were subtracted as a back-
ground. In the case of MEFs, cells were cultured with complete
culture medium (DMEM supplemented with 10% fetal bovine
serum [FBS]) for 24 h, after which the culture medium was
collected. Following centrifugation at 10,000 × g, the supernatants
were directly analyzed by ELISA without dilution. Cells were also
collected for protein measurements.
Glycan analysis of BACE1 from mouse brain
One hundred brains from 1-week-old mice were homogenized in
200 ml of buffer (TBS containing a protease inhibitor cocktail) and
then centrifuged at 500 × g for 10 min to remove the nuclei of the
cells. The supernatant was centrifuged at 105,000 × g for 2 h, after
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which the pellet was lysed with buffer (TBS containing 0.5% NP-40
and a protease inhibitor cocktail), followed by centrifugation at
105,000 × g for 2 h. 15 mg of Dynabeads protein G (Life Technolo-
gies) was added, followed by 30 min rotation to remove the IgG in
the sample. The beads were then removed, and 240 lg of rabbit
anti-BACE1 (5606, Cell Signaling Technology) and 40 mg Dyna-
beads protein G were added. After 60 h of rotation, the beads were
collected and washed three times with an excess volume of TBS
containing 0.1% NP-40. They were then further washed with 80 lg
of BACE1 C-terminal peptide (CLRQQHDDFADDISLLK, 200 lg/ml
in TBS 0.1% NP-40) to remove weakly bound proteins, followed by
TBS containing 0.1% NP-40. Proteins bound to the beads were
eluted by 800 ll of the buffer (50 mM glycine-HCl, pH 2.5),
followed by immediate neutralization by adding 18 ll of 1 M Tris–
HCl pH 8.5. The solvent was evaporated by SpeedVac, and the
proteins were dissolved and separated by SDS–PAGE. After transfer
to PDVF membrane and protein staining with Direct Blue, the band
corresponding to BACE1 or the IgG heavy chain was excised.
N-glycans from these glycoproteins were released and analyzed as
described previously (Nakano et al, 2011) with some modifications.
After release and reduction, N-glycans were desialylated by incubat-
ing with 2 M acetic acid at 80°C for 2 h. N-glycan alditols were sepa-
rated on a carbon column (5 lm HyperCarb, 1 mm I.D. × 100 mm,
Thermo Fisher Scientific) using an Accela HPLC pump (flow rate:
50 ll/min). The eluate was continuously introduced into an ESI
source (LTQ Orbitrap XL, Thermo Fisher Scientific). MS spectra
were obtained in the negative ion mode using Orbitrap MS (mass
range m/z 500 to m/z 2,500), and MS/MS spectra were obtained
using Iontrap MS. Monoisotopic masses were assigned with possible
monosaccharide compositions using the GlycoMod software tool
(mass tolerance for precursor ions is 0.005 Da).
In vitro BACE1 activity assay
Native BACE1 was extracted from the membrane fraction (obtained
from 250 ll of homogenate) of 2-week-old mouse brain tissue with
TBS containing 1% Triton X-100 and a protease inhibitor cocktail.
After centrifugation at 100,000 × g, the supernatant was subjected
to overnight immunoprecipitation with 5 lg of anti-BACE1 antibody
and 20 ll of protein G-Sepharose. The beads were washed twice
with TBS containing 0.2% Triton X-100 and used directly as an
enzyme source. For preparation of recombinant BACE1-Fc, COS-7
cells were co-transfected with pEF-Fc/BACE1, together with pCXN2,
pCXN2/GnT-III, or pCXN2/GnT-III D319A. After 6 h, the medium
was replaced with Opti-MEM I followed by further culture for
3 days. Recombinant BACE1 proteins (0.75 lg of each protein),
purified through a protein G column, were used as an enzyme
source. Assays were performed in a solution containing 100 mM
sodium acetate buffer at pH 4.5, 20 lM substrate (3212v, Peptide
Institute Inc.), 0.25% Triton X-100, protease inhibitor cocktails, and
an enzyme source in a final volume of 50 ll, followed by incubation
for 100 min at 37°C. We confirmed that for an incubation period up
to 120 min, BACE1 hydrolyzes the substrate in a time- and dose-
dependent manner. The reaction was stopped by adding 50 ll of
denaturing buffer (1% SDS, 100 mM Tris–HCl pH 9.5), and fluores-
cence was measured using a Wallac 1420 ARVOsx multilabel
counter (Perkin Elmer) at excitation and emission wavelengths of
340 nm and 405 nm, respectively.
Plasmids
The construction of pEF-Fc/human BACE1 (soluble BACE1-Fc) has
been described previously (Kitazume et al, 2001). pCXN2/human
GnT-III was constructed as described previously (Kitada et al,
2001). pCXN2/human GnT-III D319A (dominant negative form
(Ihara et al, 2002)) was constructed using a QuickChange XL Site-
Directed Mutagenesis Kit (Agilent Technologies) with primers
(GTCTTCATCATTGACGATGCGGCCGAGATCCCGGCCCGTGACG and
its complementary sequence). pLenti6/human BACE1 was con-
structed using PCR to amplify the fragment encoding full-length
BACE1 with primers (AGGGAATTCGCCACCATGGCCCAAGCCCTG
CCCTG and TCCTCACTTCAGCAGGGAGATGT). The fragment was
digested with EcoRI and then inserted into pLenti6/V5-GW/LacZ
which had been digested with EcoRI and EcoRV. The plasmid
encoding SV40 large T antigen was kindly provided by Dr. Jianguo
Gu (Tohoku Pharmaceutical University).
Immunofluorescence staining
To prepare frozen brain sections, mice were transcardially perfused
with PBS followed by 4% paraformaldehyde in PBS. Brains were
sequentially immersed in the same fixative for 16 h and 30%
sucrose in PBS for 3 days (with daily renewal of the buffer) at 4°C.
Brain sections (30 lm thick) were stained using the floating method.
Briefly, sections were incubated with PBS containing 50 lg/ml digi-
tonin and 3% BSA for 20 min at room temperature, followed by
incubation with primary antibody or biotinylated lectin (overnight at
4°C) and Alexa-labeled secondary antibody or streptavidin (30 min
at room temperature). For double staining of Ab plaques, sections
were first stained with FSB as described above (see ‘Staining of Ab
plaques’) and then stained with antibodies. Fluorescence was visual-
ized using an Olympus FV-1000 confocal microscope, with data
acquisition and quantification of the signals or co-localized area
being carried out using FV10-ASW ver.1.7 software (Olympus).
Preparation of mouse embryonic fibroblasts (MEFs)
Male and female Mgat3+/ mice were mated to obtain E13 littermate
embryos. After the head and liver were removed from each embryo,
the remaining tissues were minced. The cells from each embryo were
then incubated at 37°C for 30 min in 5 ml of PBS containing 0.05%
trypsin, 0.53 mM EDTA, and 0.004% DNase I. After the cells were
collected by centrifugation, they were resuspended and incubated
twice for 30 min in the same buffer. They were then suspended in
complete culture medium (DMEM supplemented with 10% FBS)
before being passed through a 100-lm cell strainer. After centrifugation
at 270 × g for 5 min at 4°C, the cells were resuspended in the culture
medium and plated on a 15-cm dish (one dish per embryo). Genotyp-
ing of each embryo was carried out using tissue pieces with the primers
described elsewhere (Priatel et al, 1997). The MEFs were immortalized
by transfection with a plasmid encoding SV40 large T antigen, after
which the transformed cells were selected with 400 lg/ml Zeocin.
Preparation of primary neurons
Wild-type (or Mgat3/) male and female mice were crossed, and
embryos were used at E16–18. Embryonic brains were minced in
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Neurobasal medium (Gibco) and then incubated for 5 min on ice.
After removing the supernatant, 5 ml of Neurobasal medium was
added, followed by a further 5-min incubation on ice. The cells were
then incubated in Hanks’ balanced salt solutions (HBSS, Gibco)
containing 0.25% trypsin for 15 min at 37°C. DNase I (final 0.05%)
was added, and the cells were incubated for 1 min at 37°C. After
pipetting ten times and centrifugation, the cell pellet was suspended
and incubated in HBSS containing 0.05% DNase I for 3 min at 37°C.
The cells were centrifuged and resuspended in complete culture
medium (Neurobasal medium supplemented with 2% B27 and
0.5 mM glutamine) and passed through a 100-lm strainer. They
were then seeded at 5 × 105 or 2.5 × 105/ml per dish or chamber
slide which had been precoated with poly-D-lysine. After 2 days, Ara-C
(C6645, Sigma) was added at 5 lM to kill dividing non-neuronal
cells.
Lentiviral infection
To produce the lentiviral vector, 293FT cells plated in 10-cm dishes
were simultaneously transfected with 2.25 lg of pLP1, 2.25 lg of
pLP2, 4.5 lg of pLP/VSVG, and 3 lg of pLenti6/human BACE1
using Lipofectamine 2000. The following day, the medium was
replaced with fresh medium, and after 48 h (72 h post-transfection),
the medium was collected. Cells and debris were removed by centri-
fugation, and the medium was passed through a filter (pore size
0.45 lm). The viruses were collected by centrifugation at
50,000 × g for 2 h at 20°C and then resuspended in Neurobasal
medium to concentrate the viruses (12-fold). The virus solution was
directly added to the primary neuron culture medium after 2 days in
vitro.
Cell culture and transfection
C17, COS-7, and MEF cells were cultured in DMEM supplemented
with 10% FBS. For plasmid transfection, cells at 80% confluency on
a 10-cm dish were transfected with 4–8 lg of each plasmid using
10–20 ll of Lipofectamine 2000 (for COS-7 cells).
siRNA treatment
For knockdown experiments, FlexiTube siRNAs (Qiagen) were used.
MEFs at 30% confluency on 10-cm (or 6-cm) dishes were transfect-
ed with 200 pmol (or 80 pmol) of control siRNA (AllStars negative
control siRNA, Qiagen) or siRNA for GGA3 (SI01011451) using
20 ll (or 8 ll) of Lipofectamine 2000. At 24 h or 48 h after transfec-
tion, cells were used for other experiments.
Subcellular fractionation by sucrose density
gradient centrifugation
Subcellular fractionation was performed as described previously
(Aniento et al, 1993) with modifications. All the buffers contained
20 mM Tris–HCl pH 7.5 and 3 mM imidazole. Cells were homoge-
nized with buffer containing 8.5% sucrose and protease inhibitor
cocktail by passaging 10 times through a 26-gauge needle. After
removal of nuclei and debris by centrifugation at 1,000 × g for
5 min, the concentration of sucrose was adjusted to 40.6%. The
sample (1 ml) was loaded at the bottom of a tube and overlaid with
1 ml of 35% sucrose, 1 ml of 25% sucrose, and 1 ml of the homoge-
nization buffer. After ultracentrifugation using an S52ST rotor at
150,000 × g for 90 min, interfaces at 8.5/25, 25/35, and 35/40.6%
were recovered. To sediment membranes, the collected samples
were diluted fourfold and then ultracentrifuged at 180,000 × g for
30 min. The resultant pellets were solubilized, and protein concen-
trations were measured. An equivalent amount of protein was taken
from each fraction for Western blotting. In the case of mouse brains,
the whole brain was first homogenized with seven volumes of the
same buffer containing 8.5% sucrose, after which the nuclei and
debris were removed. The postnuclear solution was adjusted to
40.6% sucrose, and 1 ml of the sample was loaded at the tube and
overlaid with 1 ml of 35% sucrose, 1 ml of 30% sucrose, and 1 ml
of 25% sucrose solutions. After ultracentrifugation using a S52ST
rotor at 100,000 × g for 90 min, the top fraction and interfaces at
25/30, 30/35, and 35/40.6% were collected. For separation of 11
fractions, a previously described method (Tan et al, 2013) was
modified. 1 ml of 44.5% sucrose was loaded in the tube and over-
laid with 3 ml of 39.7% sucrose, 3 ml of 34.2% sucrose, 3 ml of
27.4% sucrose, and 1 ml of the postnuclear solution. After ultracen-
trifugation using P40ST rotor at 120,000 × g for 16 h, each fraction
(1 ml) was collected. Equal volumes of the fractions were used for
Western blotting.
RNA extraction, reverse-transcription and quantitative PCR
Total RNA from cultured cells was extracted using TRIzol (Invitro-
gen). One microgram of total RNA was reverse-transcribed using the
SuperScript III First-Strand Synthesis System (Invitrogen) with
random hexamers. For BACE1 primers and probe, we used Assays-
on-Demand gene expression products, and cDNAs were added to
the TaqMan Universal PCR Master Mix (Applied Biosystems). The
probe for BACE1 was labeled with FAM at its 50-end and with the
quencher MGB at its 30-end. The probes for rRNA were labeled with
VIC at their 50-end and with the quencher TAMRA at their 30-end.
The cDNAs were amplified using an ABI PRISM 7900HT sequence
detection system (Applied Biosystems). The level of BACE1 mRNA
was measured in duplicate and normalized to the corresponding
rRNA level.
Human samples
The clinical study was approved by the ethical committees of
RIKEN, Tokyo Metropolitan Institute of Gerontology, and Tokyo
Metropolitan Geriatric Hospital. Frozen tissues from postmortem
brain were obtained from the Brain Bank for Aging Research, which
consists of consecutive autopsy cases from a general geriatric hospi-
tal with informed consent obtained from the relatives for each
autopsy. Handling of the brains and diagnostic criteria have been
described previously (Akasaka-Manya et al, 2010). One gram of
temporal pole tissue was sampled from 10 cases each with AD or
early AD, and age-matched controls (the same cases as reported in
the previous study(Akasaka-Manya et al, 2010)). A summary of the
clinical and histological data is shown in Fig 2A. The brains were
homogenized with five volumes of buffer (20 mM Tris–HCl, pH 7.4,
150 mM NaCl, 5 mM EDTA, and protease inhibitor cocktail) using
stainless steel beads (7.9 mm) in Micro Smash (TOMY) for 40 (1st)
and 20 (2nd) seconds at 3,500 rpm. The homogenates were
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ultracentrifuged at 100,000 × g for 1 h to obtain membrane
fractions. BACE1 immunoprecipitation and Western blotting were
carried out (no blinding) as described above for mouse brain with
slight modifications. We used magnetic Dynabeads protein G for
protein pulldown. The lysates were first pre-cleared by the beads in
the absence of antibody addition.
Construction of a three-dimensional model of N-glycosylated
human BACE1
A 3D structural model of human BACE1 with bisected N-glycans was
generated by GlyProt (Bohne-Lang & von der Lieth, 2005). The
atomic coordinate of unglycosylated human BACE1 (PDB code: 2qp8)
was used for the construction of the glycosylated model (Shimizu
et al, 2008), and the bisected N-glycans (GlcNAc1Man3GlcNAc2)
were attached to four N-glycosylation sites, Asn153, Asn172,
Asn223, and Asn354.
Statistical analysis
All data are shown as mean  SEM. For comparison of the means
between two groups, statistical analysis was performed by applying
an unpaired one-sided Student’s t-test after confirming equality
between two groups and normality by a Kolmogorov–Smirnov test.
If these tests were not passed, a Mann–Whitney U-test was
performed. Comparisons of the means among more than two groups
were done by a one-way or two-way analysis of variance (ANOVA)
followed by a post hoc test, in which a Student–Newman–Keuls test
(SigmaPlot software, ver.11; Systat Software Inc.) or Tukey–Kramer
test was applied. P-values < 0.05 were considered to be significant.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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The paper explained
Problem
Alzheimer’s disease (AD) is the most common dementia and is a serious
issue in aging populations throughout the world. However, efforts to
develop therapeutic agents for AD have so far achieved limited success.
The deposition of amyloid b (Ab) peptide in the brain, resulting in Ab
plaques, is the biochemical hallmark of AD. Currently, one of the most
promising targets for AD therapy is the enzyme BACE1 (b-site amyloid
precursor protein cleaving enzyme-1), which generates Ab from its
precursor protein. Several BACE1 inhibitors are in clinical trials, but
there is a concern about side effects, given that BACE1 also cleaves
other proteins in the brain. Indeed, Bace1 knockout mice exhibit severe
phenotypes such as schizophrenia-like symptoms, muscle abnormality,
retinal pathology, and early lethality. Therefore, modulation of BACE1
function with fewer detrimental side effects would be a rational and
promising strategy to ameliorate AD pathology. However, little is known
about the regulation of BACE1 function at the level of cellular expres-
sion and compartmental localization during health and disease.
Results
In this study, we show that a unique sugar modification, ‘bisecting
GlcNAc’, on BACE1 is a novel regulator of cellular BACE1 stability. We
found that BACE1 is abnormally modified, with higher levels of bisect-
ing GlcNAc being observed in AD patients, suggesting the pathological
involvement of this sugar modification on BACE1 during AD develop-
ment. Using AD model mice and knockout mice lacking the glycosyl
enzyme (GnT-III) responsible for the biosynthesis of bisecting GlcNAc,
we demonstrated that the loss of bisecting GlcNAc diminishes Ab
plaque formation by reducing BACE1-mediated Ab generation. The
decrease in Ab generation in the knockout mice was caused by a shift
in the intracellular distribution of BACE1 from early endosomes
(where Ab precursor protein is localized) to late endosomes/lysosomes,
leading to faster lysosomal degradation of BACE1. These results indi-
cate that bisecting GlcNAc is a novel pathological modification of
BACE1 which delays its degradation.
Impact
Knockout mice for bisecting GlcNAc exhibit a robust reduction in Ab
production but show almost no abnormality in contrast to the severe
phenotypes of Bace1 knockout mice. The latter phenotypes are caused
by the impaired cleavage of physiological BACE1 substrates, whereas we
found that a BACE1 substrate other than Ab-precursor protein is
normally cleaved in GnT-III-deficient mice, suggesting that the inhibi-
tory effects of bisecting GlcNAc on BACE1 are selective to the
Ab-generation pathway. Therefore, inhibiting the biosynthesis of bisect-
ing GlcNAc could block the AD-related pathological effect of BACE1,
while having only weak detrimental effects on normal physiological
BACE1 functions. These findings suggest that the biosynthetic pathway
for bisecting GlcNAc could serve as a novel and promising drug target
for AD therapy, resulting in fewer side effects than BACE1 inhibitors.
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